Stock_Info_Plus

All posts are my opinion. Please always do your own research.

[Stock_Info_Plus @Stock_Info_Plus]

We added to our $GRCE position today. $2.32 per share. Lowering our cost average to $2.50.

[Stock_Info_Plus @Stock_Info_Plus]

We’ve added to our $GRCE position. Bringing our average cost up to $2.59 per share.

[Stock_Info_Plus @Stock_Info_Plus]

We’re back in on $OTLK. $1.21 a share. FDA approval date July 29th. https://t.co/4dT6ae69dM

[Stock_Info_Plus @Stock_Info_Plus]

@Biotechmaster12 Think I held on a week too long. It was over $3 last week.

[Stock_Info_Plus @Stock_Info_Plus]

We sold our position in $SPRO. $2.92 a share. 23.32% profit.

[Stock_Info_Plus @Stock_Info_Plus]

We invested $SPRO today. FDA approval date June 18th

[Stock_Info_Plus @Stock_Info_Plus]

@LyfeOfKarma We’re not in for long term. Just the FDA approval dates.

[Stock_Info_Plus @Stock_Info_Plus]

$CING received a CRL this morning. With this news we’ve re entered at $3.75 a share.

[Stock_Info_Plus @Stock_Info_Plus]

We’re of $CING. $4.49 a share. 8.19% profit. Not great. But not a loss

[Stock_Info_Plus @Stock_Info_Plus]

We’ve added to our $GRCE position. Bringing our average cost up to $2.59 per share.

[Stock_Info_Plus @Stock_Info_Plus]

We bought back into $GRCE on April 24th at $2:30 a share.

[Stock_Info_Plus @Stock_Info_Plus]

@day_trading_101 $SPRO June 18th

[Stock_Info_Plus @Stock_Info_Plus]

$MNKD approved. We’re out $3.80 a share. 22.65% profit.

[Stock_Info_Plus @Stock_Info_Plus]

We added to our $MNKD position yesterday $2.63 a share bringing our average down to $3.10 a share. This one hasn’t gone well for us at all. Trying to lower our cost average with very little time left.

[Stock_Info_Plus @Stock_Info_Plus]

We’re out of $OTLK. $0.73 a share. 15.84% profit. We’ll gladly take it. Down over 60% at one stage.

[Stock_Info_Plus @Stock_Info_Plus]

With this mornings news we added to our position. Bringing our cost average down to $0.6302. $OTLK.

[Stock_Info_Plus @Stock_Info_Plus]

With this mornings news we added to our position. Bringing our cost average down to $0.6302. $OTLK.

[Stock_Info_Plus @Stock_Info_Plus]

We purchased more $OTLK yesterday at $0.256. Bringing our average cost down to $0.7765

[Stock_Info_Plus @Stock_Info_Plus]

We sold our stake in $NRXP. $3.42 a share. 71.08% profit. Earnings are Monday. Taking our profit in case of a bad earnings report. We might reenter.

[Stock_Info_Plus @Stock_Info_Plus]

We added to our $NRXP position today at $1.88 a share bringing our average cost down to $2.00 a share.

[Stock_Info_Plus @Stock_Info_Plus]

We’re of $CING. $4.49 a share. 8.19% profit. Not great. But not a loss

[Stock_Info_Plus @Stock_Info_Plus]

We took a small position in $CING today. Our price point is $4.15. Approvals date 5/31
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date https://t.co/Z3LoFbN7cY

[Stock_Info_Plus @Stock_Info_Plus]

We added to our $MIST position lowering our cost average to $1.72 a share. This one not going to plan either.

[Stock_Info_Plus @Stock_Info_Plus]

We’re back in on $MIST. $2.21 a share. We feel it’s over sold and will pop.

[Stock_Info_Plus @Stock_Info_Plus]

We added to our $MNKD position yesterday $2.63 a share bringing our average down to $3.10 a share. This one hasn’t gone well for us at all. Trying to lower our cost average with very little time left.

[Stock_Info_Plus @Stock_Info_Plus]

We purchased more $MNKD after selling $GRCE $2.81 a share. This brings our cost average down to $3.16 a share.

[Stock_Info_Plus @Stock_Info_Plus]

We bought back into $GRCE on April 24th at $2:30 a share.

[Stock_Info_Plus @Stock_Info_Plus]

We bought into $BTAI on April 20th. $1.20 a share. FDA approval November 14th.

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting https://t.co/RDg3gr9W3z

[Stock_Info_Plus @Stock_Info_Plus]

@Biotechmaster12 Yes that was our fear also so didn’t add to our position.

[Stock_Info_Plus @Stock_Info_Plus]

We’ve sold our $GRCE position. $4.92 a share. We’re walking away with a 54.8% profit.

[Stock_Info_Plus @Stock_Info_Plus]

We took a small position in $GRCE today. Our price point is $3.18. Approvals date 4/23 https://t.co/HCIfxvjK1U

[Stock_Info_Plus @Stock_Info_Plus]

We purchased more $MNKD after selling $GRCE $2.81 a share. This brings our cost average down to $3.16 a share.

[Stock_Info_Plus @Stock_Info_Plus]

We added to our $MNKD position today. $2.73 a share bringing our cost average down to $3.28 https://t.co/jpQzSLumTp

[Stock_Info_Plus @Stock_Info_Plus]

@Biotechmaster12 We don’t do reentries got burned a few times. Was hoping to sell last week but it collapsed in price on the Monday. So hung on in there till today.